marijuana stocks news

GW Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference on 29 November

GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, 29 November 2016, at 10:30 a.m. ET at the Lotte New York Palace, New York City.

A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Sundial Growers Inc. (SNDL) Announces US$74.5 Million Registered Offering and Full Utilization of Shelf Registration Statement

Sundial Growers Announces US$74.5 Million Registered Offering and Full Utilization of Shelf…

$INSY to Report Fourth Quarter and Year-End 2014 Results

Insys Therapeutics to Report Fourth Quarter and Year-End 2014 Results PHOENIX, AZ–(Marketwired…

TransCanna (TCAN.CN) Announces the Completion of 420 Global

TransCanna Announces the Completion of 420 Global TransCanna Holdings Inc. (TH8) (“TransCanna”…

$NTRR Joint Venture Partner Prepares to Launch BeKind Topicals Brand

NTRR Joint Venture Partner Prepares to Launch BeKind Topicals Brand in Explosive…